Pulmonary Disease Overview

Principles

Definition

Pulmonary disease is a broad category of medical conditions affecting the lungs and the associated respiratory system. This research concept investigates the etiology, pathophysiology, diagnosis, treatment, and prevention of disorders impacting the airways, lung parenchyma, and pulmonary vasculature, representing a significant global health burden.

Ontological type

Therapeutic Strategies

Etiological Factors

Diagnostic Modalities

Key developments

Key Figures

Physiology-Based Paradigm era

Peter T. Macklem [1] is associated with Harvard University [3] and Johns Hopkins University [4] during this era. His key contributions include Site and Nature of Airway Obstruction in Chronic Obstructive Lung Disease [6], Frequency dependence of compliance as a test for obstruction in the small airways [7], and Frequency dependence of flow resistance in patients with obstructive lung disease [8], which anchored the physiology-based, measurement-driven approach of the era. James C. Hogg [2] is associated with Johns Hopkins University [4] and McGill University [5] during this era. His contribution, embodied by Site and Nature of Airway Obstruction in Chronic Obstructive Lung Disease [6], advanced the physiological characterization of obstruction and its role in functional assessment.

Protease-Driven Remodeling era

Michael A. Matthay [1] was a leading figure whose work during this era spanned Harvard University [3] and the University of California, San Francisco [4]. He helped expand the Adult Respiratory Distress Syndrome definition in the 1988 paper An Expanded Definition of the Adult Respiratory Syndrome [7], and his ARDS-focused work, including The Acute Respiratory Distress Syndrome [6] and the discovery of elevated NAP-1/Interleukin-8 in airspaces [8], shaped the era’s emphasis on protease-driven inflammation and biomarker-driven stratification. Lorraine B. Ware [2] was a prominent investigator with affiliations at University of California, San Francisco [4] and University of California, Los Angeles [5] during this era. Her key contribution centers on synthesizing ARDS pathophysiology for this protease-driven remodeling era, most prominently in The Acute Respiratory Distress Syndrome [6], which informed clinical definitions and biomarker-oriented approaches.

Molecular Phenotyping and Fibrogenesis era

Graham L. Hall[1] operated across the Medical University of Vienna[3] and the University of Bern[4] during this era, contributing to pulmonary research that informs molecular phenotyping and fibrogenesis. His key contributions, based on the global lung function 2012 equations paper[7], include establishing multi-ethnic spirometry reference values for the 3–95-year age range, which enabled more accurate phenotypic stratification and cross-population comparability in lung disease. Janet Stocks[2], affiliated with Erasmus University Rotterdam[5] and University College London[6], embodies the era's emphasis on respiratory physiology and large-scale normative datasets. Her contribution, anchored in the same global lung function 2012 equations paper[7], helped standardize spirometric interpretation across populations and ages, advancing phenotype-driven assessment and therapy-guided trial design in pulmonary fibrogenesis.